Panoply™ Human MAP2K2 Over-expressing Stable Cell Line

Clear cell renal cell carcinoma (ccRCC) is one of the most common and aggressive malignant tumors of the urinary system. Although vascular endothelial growth factor receptor inhibitors (VEGFRi) are first-line treatments for advanced ccRCC, their efficacy is significantly limited by the presence of initial and acquired resistance, hindering complete tumor eradication. Here, researchers used a CRISPR/Cas9 library screening method to identify MAP2K2 as a gene associated with resistance to three commonly used VEGFR inhibitors (sunitinib, axitinib, and sorafenib). The study found a significant positive correlation between MAP2K2 expression levels and resistance to these VEGFR inhibitors. Drug-resistant cell lines established through dose escalation showed increased MAP2K2 expression and activation of the MEK/ERK signaling pathway. Notably, combining MEK inhibitors (MEKis) with VEGFR inhibitors significantly increased the drug sensitivity of these resistant cells, leading to a significant increase in cell death. Furthermore, the study also found a positive feedback regulatory mechanism between SP1 and MAP2K2, where SP1 and MAP2K2 mutually promote each other's expression, thus maintaining the activation of the MEK/ERK pathway. This study demonstrates that MEKi can effectively restore drug sensitivity in VEGFRi-resistant cells, providing a promising therapeutic strategy for overcoming VEGFRi resistance in ccRCC.

Here, researchers constructed stable MAP2K2 knockdown and overexpression cell lines (MAP2K2-sh and MAP2K2-oe) in ccRCC cell lines 786-O and OS-RC-2 (Figure 1A, B). Notably, knockdown or overexpression of MAP2K2 also inhibited or enhanced the activation level of pERK1/2, thereby regulating the MEK/ERK pathway (Figure 1B). Next, the researchers used the CCK-8 assay to determine the half-maximal inhibitory concentration (IC50) values of Sunitinib, Axitinib, and Sorafenib in MAP2K2 knockdown and MAP2K2 overexpression cells (Figure 1C, D). In each experimental group, MAP2K2 knockdown reduced the IC50 values of the three VEGFRis, whereas MAP2K2 overexpression increased the IC50 values. Visual quantitative analysis of the IC50 results from three independent experiments showed that MAP2K2 knockdown increased the sensitivity of ccRCC cells to VEGFR inhibitors, while MAP2K2 overexpression enhanced drug resistance (Figure 1E, F). These results indicate that MAP2K2 expression regulates the activation of the MEK/ERK pathway, which in turn affects the sensitivity of ccRCC cells to VEGFR inhibitors.

Figure 1. MEK/ERK Pathway Activation was Correlated Positively with VEGFRi Resistance. (Xia Z, et al., 2025)